Table 2.
Model inputs: costs
|
Event cost ($) |
|||
|---|---|---|---|
| Base-case | Lower bound | Upper bound | |
|
Treatment Costs |
|
|
|
| Cost of annual treatment |
|
|
|
| Asenapine |
1,030.00 |
N/A |
N/A |
| Olanzapine [41] |
1,871.00 |
1,316.00 |
2,426.00 |
| -Cost of EPS management [42] |
60.00 |
0.00 |
N/A |
| Costs associated with long-term metabolic complications |
|
||
|
Direct costs* |
|
|
|
| Diabetes |
3,834.77 |
1,215.00 |
17,072.00 |
| Hypertension |
571.00 |
233.00 |
827.00 |
| CHDs |
|
|
|
| Fatal CHDs |
7,093.20 |
775.00 |
52,617.00 |
| CHDs (Year 1) |
2,481.24 |
818.00 |
8,819.00 |
| CHDs (Year 2–5) |
1,146.11 |
360.00 |
5,795.00 |
| Stroke |
|
|
|
| Fatal stroke |
30,776.93 |
7,362.00 |
34,165.00 |
| Stroke (Year 1) |
4,034.86 |
1,395.00 |
10,560.00 |
| Stroke (Year 2–5) |
1,867.59 |
452.00 |
8,692.00 |
|
Productivity losses[28,43]–[46] |
|
|
|
| Diabetes |
528.00 |
396.00 |
660.00 |
| Hypertension |
119.00 |
89.25 |
148.75 |
| CHDs |
3,109.00 |
2,331.75 |
3,886.25 |
| Stroke |
4,322.00 |
3,241.50 |
5,402.50 |
|
Informal care[47] |
|
|
|
| Stroke | 3,770.00 | 2,827.50 | 4,712.50 |
*Estimated from the RAMQ database.